Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment.
BACKGROUND:We previously demonstrated the benefits of daily, oral pentosan polysulfate (PPS) treatment in a rat model of mucopolysaccharidosis (MPS) type VI. Herein we compare these effects to once weekly, subcutaneous (s.c.) injection. The bioavailability of injected PPS is greater than oral, sugge...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4071040?pdf=render |
| _version_ | 1818584785255137280 |
|---|---|
| author | Michael Frohbergh Yi Ge Fanli Meng Nesrin Karabul Alexander Solyom Alon Lai James Iatridis Edward H Schuchman Calogera M Simonaro |
| author_facet | Michael Frohbergh Yi Ge Fanli Meng Nesrin Karabul Alexander Solyom Alon Lai James Iatridis Edward H Schuchman Calogera M Simonaro |
| author_sort | Michael Frohbergh |
| collection | DOAJ |
| description | BACKGROUND:We previously demonstrated the benefits of daily, oral pentosan polysulfate (PPS) treatment in a rat model of mucopolysaccharidosis (MPS) type VI. Herein we compare these effects to once weekly, subcutaneous (s.c.) injection. The bioavailability of injected PPS is greater than oral, suggesting better delivery to difficult tissues such as bone and cartilage. Injected PPS also effectively treats osteoarthritis in animals, and has shown success in osteoarthritis patients. METHODOLOGY/PRINCIPAL FINDINGS:One-month-old MPS VI rats were given once weekly s.c. injections of PPS (1, 2 and 4 mg/kg, human equivalent dose (HED)), or daily oral PPS (4 mg/kg HED) for 6 months. Serum inflammatory markers and total glycosaminoglycans (GAGs) were measured, as were several histological, morphological and functional endpoints. Overall, weekly s.c. PPS injections led to similar or greater therapeutic effects as daily oral administration. Common findings between the two treatment approaches included reduced serum inflammatory markers, improved dentition and skull lengths, reduced tracheal deformities, and improved mobility. Enhanced effects of s.c. treatment included GAG reduction in urine and tissues, greater endurance on a rotarod, and better improvements in articular cartilage and bone in some dose groups. Optimal therapeutic effects were observed at 2 mg/kg, s.c.. No drug-related increases in liver enzymes, coagulation factor abnormalities or other adverse effects were identified following 6 months of s.c. PPS administration. CONCLUSIONS:Once weekly s.c. administration of PPS in MPS VI rats led to equal or better therapeutic effects than daily oral administration, including a surprising reduction in urine and tissue GAGs. No adverse effects from s.c. PPS administration were observed over the 6-month study period. |
| first_indexed | 2024-12-16T08:26:41Z |
| format | Article |
| id | doaj.art-33938f5f1c0446a886807e8274d52f6b |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-16T08:26:41Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-33938f5f1c0446a886807e8274d52f6b2022-12-21T22:37:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0196e10088210.1371/journal.pone.0100882Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment.Michael FrohberghYi GeFanli MengNesrin KarabulAlexander SolyomAlon LaiJames IatridisEdward H SchuchmanCalogera M SimonaroBACKGROUND:We previously demonstrated the benefits of daily, oral pentosan polysulfate (PPS) treatment in a rat model of mucopolysaccharidosis (MPS) type VI. Herein we compare these effects to once weekly, subcutaneous (s.c.) injection. The bioavailability of injected PPS is greater than oral, suggesting better delivery to difficult tissues such as bone and cartilage. Injected PPS also effectively treats osteoarthritis in animals, and has shown success in osteoarthritis patients. METHODOLOGY/PRINCIPAL FINDINGS:One-month-old MPS VI rats were given once weekly s.c. injections of PPS (1, 2 and 4 mg/kg, human equivalent dose (HED)), or daily oral PPS (4 mg/kg HED) for 6 months. Serum inflammatory markers and total glycosaminoglycans (GAGs) were measured, as were several histological, morphological and functional endpoints. Overall, weekly s.c. PPS injections led to similar or greater therapeutic effects as daily oral administration. Common findings between the two treatment approaches included reduced serum inflammatory markers, improved dentition and skull lengths, reduced tracheal deformities, and improved mobility. Enhanced effects of s.c. treatment included GAG reduction in urine and tissues, greater endurance on a rotarod, and better improvements in articular cartilage and bone in some dose groups. Optimal therapeutic effects were observed at 2 mg/kg, s.c.. No drug-related increases in liver enzymes, coagulation factor abnormalities or other adverse effects were identified following 6 months of s.c. PPS administration. CONCLUSIONS:Once weekly s.c. administration of PPS in MPS VI rats led to equal or better therapeutic effects than daily oral administration, including a surprising reduction in urine and tissue GAGs. No adverse effects from s.c. PPS administration were observed over the 6-month study period.http://europepmc.org/articles/PMC4071040?pdf=render |
| spellingShingle | Michael Frohbergh Yi Ge Fanli Meng Nesrin Karabul Alexander Solyom Alon Lai James Iatridis Edward H Schuchman Calogera M Simonaro Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment. PLoS ONE |
| title | Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment. |
| title_full | Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment. |
| title_fullStr | Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment. |
| title_full_unstemmed | Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment. |
| title_short | Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment. |
| title_sort | dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type vi rats and comparison to oral treatment |
| url | http://europepmc.org/articles/PMC4071040?pdf=render |
| work_keys_str_mv | AT michaelfrohbergh doseresponsiveeffectsofsubcutaneouspentosanpolysulfateinjectioninmucopolysaccharidosistypeviratsandcomparisontooraltreatment AT yige doseresponsiveeffectsofsubcutaneouspentosanpolysulfateinjectioninmucopolysaccharidosistypeviratsandcomparisontooraltreatment AT fanlimeng doseresponsiveeffectsofsubcutaneouspentosanpolysulfateinjectioninmucopolysaccharidosistypeviratsandcomparisontooraltreatment AT nesrinkarabul doseresponsiveeffectsofsubcutaneouspentosanpolysulfateinjectioninmucopolysaccharidosistypeviratsandcomparisontooraltreatment AT alexandersolyom doseresponsiveeffectsofsubcutaneouspentosanpolysulfateinjectioninmucopolysaccharidosistypeviratsandcomparisontooraltreatment AT alonlai doseresponsiveeffectsofsubcutaneouspentosanpolysulfateinjectioninmucopolysaccharidosistypeviratsandcomparisontooraltreatment AT jamesiatridis doseresponsiveeffectsofsubcutaneouspentosanpolysulfateinjectioninmucopolysaccharidosistypeviratsandcomparisontooraltreatment AT edwardhschuchman doseresponsiveeffectsofsubcutaneouspentosanpolysulfateinjectioninmucopolysaccharidosistypeviratsandcomparisontooraltreatment AT calogeramsimonaro doseresponsiveeffectsofsubcutaneouspentosanpolysulfateinjectioninmucopolysaccharidosistypeviratsandcomparisontooraltreatment |